Concepedia

Dirk Müller

DM

Statistics

Publications

25

Citations

1.7K

H-Index

18

Active since

1997

Affiliations

Zentralklinik Bad Berka(Current)

University of Lübeck

Klinikum Aschaffenburg

Vivantes Klinikum

University of Cologne

Dirk Müller is an author at Zentralklinik Bad Berka specializing in medicine, nuclear medicine, and cardiology.

ORCID

Publications per year

1997–2024

25

Publications

25

Molecular Imaging of <i>HER2</i>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic <sup>111</sup>In- or <sup>68</sup>Ga-Labeled Affibody Molecules

Richard P. Baum, Vikas Prasad, Dirk Müller et al. · Journal of Nuclear Medicine · 2010 · 307 citations · Full text

, , +17

Prostate-Specific Membrane Antigen Radioligand Therapy Using <sup>177</sup>Lu-PSMA I&amp;T and <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Christiane Schuchardt, Jingjing Zhang, Harshad Kulkarni et al. · Journal of Nuclear Medicine · 2021 · 177 citations · Full text

, , +17

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with <sup>177</sup> Lu DOTA-TATE and <sup>177</sup> Lu DOTA-NOC

Christiane Wehrmann, Stefan Senftleben, Carolin Zachert et al. · Cancer Biotherapy and Radiopharmaceuticals · 2007 · 175 citations

, , +17

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

Jingjing Zhang, Harshad Kulkarni, Aviral Singh et al. · Journal of Nuclear Medicine · 2018 · 122 citations

, , +17

First-in-Humans Study of the SSTR Antagonist <sup>177</sup>Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Richard P. Baum, Jingjing Zhang, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2021 · 108 citations · Full text

, , +16

1–5 of 25